Simplify Logo

Full-Time

Associate Scientist

Biology, CNS In Vivo

Confirmed live in the last 24 hours

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

501-1,000 employees

Develops RNAi-based therapies for diseases

Biotechnology
Healthcare

Compensation Overview

$65k - $80kAnnually

Entry, Junior

San Diego, CA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • BS and/or MS in biology related field
  • Extensive experience with small animal handling
  • Experience with sample collection / tissue collection
  • Excellent record keeping and experience in data analysis, graphing and presentation
  • Ability to work independently and to handle multiple projects and deadlines
  • Demonstrated innovation, creativity and resilience in problem solving
  • Excellent oral and written communication skills
  • Self-motivated team player with the ability to thrive in a fast paced, multi-disciplinary, matrixed environment
Responsibilities
  • Perform in vivo studies and ex vivo analysis to facilitate drug discovery and development in various diseases
  • Establish new preclinical animal disease models
  • Perform animal behavior studies as needed
  • Coordinate processes across departments and with outside vendors to enable efficient study execution and data generation
  • Read and apply relevant scientific literature to projects to troubleshoot and solve problems
  • Present research findings to project teams and prepare technical reports
  • Maintain a high level of productivity in the lab and perform critical experiments
Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

View

Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing specific genes. The company uses RNA interference (RNAi), a natural process that reduces gene expression, to create therapies that can potentially stop or reverse diseases like cystic fibrosis and hepatitis B. Their approach involves a variety of RNA chemistries and effective delivery methods to ensure that the target genes are significantly reduced in activity. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, which allows them to address medical needs that are not met by existing treatments. The goal of Arrowhead Pharmaceuticals is to provide new treatment options for patients suffering from genetic disorders, leveraging their expertise and partnerships to bring these therapies to market.

Company Stage

IPO

Total Funding

$899.9M

Headquarters

Pasadena, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Arrowhead's recent $450 million funding round provides substantial financial resources to advance its drug pipeline and expand research initiatives.
  • Positive Phase 2 data for plozasiran and the initiation of an Expanded Access Program highlight the company's commitment to addressing unmet medical needs.
  • The company's diversified pipeline, including treatments for cystic fibrosis, hepatitis B, and myotonic dystrophy, offers multiple avenues for success.

What critics are saying

  • The high costs and lengthy timelines associated with drug development could strain Arrowhead's financial resources despite recent funding.
  • Regulatory hurdles and the potential for clinical trial failures pose significant risks to the company's drug approval process.

What makes Arrowhead Pharmaceuticals unique

  • Arrowhead Pharmaceuticals leverages RNA interference (RNAi) technology to target and silence disease-causing genes, setting it apart from traditional pharmaceutical approaches.
  • The company's proprietary TRiM platform enables tissue-specific targeting, enhancing the efficacy and safety of its therapies.
  • Strategic partnerships with major pharmaceutical companies like Takeda bolster Arrowhead's credibility and expand its research capabilities.